Search

Your search keyword '"Wissing, M"' showing total 195 results
Start Over Author "Wissing, M"
195 results on '"Wissing, M"'

2. Conversations as Carriers of Meaning to a Common Good

Author

Marujo, H. Á., Neto, L. M., Wissing, M. P., Tonon, Graciela, Series Editor, Michalos, Alex, Editorial Board Member, Phillips, Rhonda, Editorial Board Member, Rahtz, Don, Editorial Board Member, Webb, Dave, Editorial Board Member, Glatzer, Wolfgang, Editorial Board Member, Lee, Dong Jin, Editorial Board Member, Camfield, Laura, Editorial Board Member, and Eloff, Irma, editor

Published
2019
Full Text
View/download PDF

4. Mikroplastik in gestauten Gewässern in Nordrhein-Westfalen - Ergebnisse aus dem Projekt MikroPlaTaS

Author

Wendt-Potthoff, Katrin, Wissing, M., Gabel, F., Wendt-Potthoff, Katrin, Wissing, M., and Gabel, F.

Abstract

Plastik und Mikroplastik werden in praktisch allen Gewässern gefunden, auch an entlegenen Orten. Über Flüsse wird ein maßgeblicher Teil des Plastiks in die Meere transportiert. Es gibt Hinweise, dass Talsperren und Stauhaltungen außer Sedimenten auch Mikroplastik zurückhalten. Gezielte Untersuchungen dazu gibt es aber kaum. Im Rahmen des Projektverbundes MikroPlaTaS wurden drei Gewässer mit Staubereichen in NRW untersucht. In allen wurden mehrere Kunststoffsorten in Form von Mikroplastik nachgewiesen.

Published
2023

7. Diagnostisch hulpmiddel dementie bij mensen met (zeer) ernstige verstandelijke (en meervoudige) beperkingen: ontwikkeling en eerste praktijktoets.

Author

Wissing, M., Koudenburg, S., van der Wal, I., Groen, M., van Dam, L., Hobbelen, J., De Deyn, P., Waninge, A., and Dekker, A.

Subjects
DIAGNOSIS of dementia, EXPERIMENTAL design, RESEARCH evaluation, RESEARCH methodology, ATTITUDES of medical personnel, MEDICAL screening, EVIDENCE-based medicine, INTERVIEWING, DESCRIPTIVE statistics
Abstract

Copyright of Nederlands Tijdschrift voor de Zorg aan Mensen met Veerstandelijke Beperkingen is the property of Uitgeverij van Gorcum and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023

8. Socio-Demographic Variables, General Psychological Well-Being and the Mental Health Continuum in an African Context

Author

Khumalo, I. P., Temane, Q. M., and Wissing, M. P.

Abstract

Age, gender, marital status, education attainment, employment status, and environmental setting explain different amounts of variance in psychological well-being and mental health. Inconsistent findings are reported for the socio-demographic variables in psychological well-being depending amongst others on the definition and measurement of well-being, context and the nature of the population. The present study explored the association of socio-demographic variables in an African context using two models that conceptualise and measure well-being as a holistic integrated and complex construct, namely the General Psychological Well-being model (GPW) and the Mental Health Continuum model (MHC). The study was conducted among an African sample in the North West Province of South Africa. A sample of 459 male and female Setswana-speaking adults from rural and urban areas completed measures of general psychological well-being and the mental health continuum. Descriptive statistics, correlations, cross-tabulations and regression analyses were computed. Findings indicate that socio-demographic variables play a role in determining holistic psychological well-being in a South African Setswana-speaking community. Urban living, employment, education and being married were associated with higher psychological well-being. Rural or urban environmental setting, followed by employment status, accounted for the greatest variance in psychological well-being measures. Age and gender were not significantly associated with well-being. The findings suggest that the current state of African rural living is detrimental to well-being. Through employment being an index of socio-economic status, the unemployed experience poor well-being. Future research efforts to explore the mechanisms of these relationships, and context-relevant intervention programmes are recommended.

Published
2012
Full Text
View/download PDF

13. Predictors of South African male testosterone levels: The THUSA study

Author

Gray, P. B., Kruger, A., Huisman, H. W., Wissing, M. P., and Vorster, H. H.

Subjects
Testosterone -- Health aspects, South Africans -- Health aspects, Biological sciences
Abstract

A study to test predictions concerning variation in South African male testosterone levels among subgroups across an urbanization gradient representing differences in both geography and socioeconomic status is presented. Differences in testosterone levels among subgroups are insignificant and urbanization-related differences in testosterone levels are notable.

Published
2006

14. The Added Value of Sentinel Node Mapping in Endometrial Cancer

Author

Kogan, L., primary, Matanes, E., additional, Wissing, M., additional, Mitric, C., additional, How, J., additional, Amajoud, Z., additional, Abitbol, J., additional, Yasmeen, A., additional, Lopez-ozuna, V., additional, Eisenberg, N., additional, Lau, S., additional, Salvador, S., additional, and Gotlieb, W.H., additional

Published
2020
Full Text
View/download PDF

17. Predicting histologic upgrading in endometrial cancer

Author

Matanes, E., primary, Mitric, C., additional, Wissing, M., additional, Amajoud, Z., additional, Abitbol, J., additional, Eisenberg, N., additional, López-Ozuna, V., additional, Raban, O., additional, Yasmeen, A., additional, Salvador, S., additional, Lau, S., additional, Gotlieb, W.H., additional, and Kogan, L., additional

Published
2020
Full Text
View/download PDF

18. Prolonged waiting times for surgery in patients with endometrial cancer is associated with lymph-vascular space invasion but has limited effect on clinical outcome

Author

Mitric, C., primary, Wissing, M., additional, Matanes, E., additional, Amajoud, Z., additional, Abitbol, J., additional, Eisenberg, N., additional, López-Ozuna, V., additional, Yasmeen, A., additional, Salvador, S., additional, Lau, S., additional, Gotlieb, W.H., additional, and Kogan, L., additional

Published
2020
Full Text
View/download PDF

25. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up

Author

Harper, L1, Morgan, Md, Walsh, M, Hoglund, P, Westman, K, Flossmann, O, Tesar, V, Vanhille, P, de Groot, K, Luqmani, R, Flores Suarez LF, Watts, R, Pusey, C, Bruchfeld, A, Rasmussen, N, Blockmans, D, Savage, Co, Jayne, D, EUVAS i. n. v. e. s. t. i. g. a. t. o. r. s. Abramowicz, D, Wissing, M, Madhoun, P, Stolear, J, Ekstrand, A, Chabova, V, Rychlik, I, Bataille, P, Puechal, X, Leblau, J, Esnault, Vl, Gross, Wl, Weidner, S, Rupprecht, H, Schneider, M, Specker, C, Schmitt, W, van der Woude, F, Vischedyck, M, Feighery, C, Garibotto, Giacomo, Sinico, Ra, Santostefano, M, Dadoniene, J, Hagen, Ec, Oudejans, I, Verburgh, C, Ballarin, J, Mirapeix, E, Valles, M, Pettersson, E, Eriksson, P, Selga, D, Segelmark, M, Sterner, G, Lundberg, I, Svenungsson, E, Chizzolini, C, Adu, D, de Souza, R., and Chizzolini, Carlo

Subjects
Male, Time Factors, Administration, Oral, Kidney, law.invention, Cyclophosphamide/administration & dosage, Randomized controlled trial, law, Risk Factors, Secondary Prevention, Immunology and Allergy, ddc:616, Aged, 80 and over, ANCA, Remission Induction, Middle Aged, Female, Vasculitis, Immunosuppressive Agents, medicine.drug, Systemic vasculitis, Adult, medicine.medical_specialty, Cyclophosphamide, Adolescent, Kidney/physiology, Immunology, General Biochemistry, Genetics and Molecular Biology, Antibodies, Antineutrophil Cytoplasmic, Young Adult, Rheumatology, Internal medicine, medicine, Kidney Function, Humans, Adverse effect, Immunosuppressive Agents/administration & dosage, Aged, Retrospective Studies, business.industry, Vasculitis/drug therapy/immunology/mortality, Antibodies, Antineutrophil Cytoplasmic/immunology, Retrospective cohort study, medicine.disease, Surgery, Regimen, Pulse Therapy, Drug, business, Follow-Up Studies
Abstract

INTRODUCTION: The previously reported randomised controlled trial of a consensus regimen of pulse cyclophosphamide suggested that it was as effective as a daily oral (DO) cyclophosphamide for remission induction of antineutrophil cytoplasm autoantibodies-associated systemic vasculitis when both were combined with the same glucocorticoid protocol (CYCLOPS study (Randomised trial of daily oral versus pulse Cyclophosphamide as therapy for ANCA-associated Systemic Vasculitis published de groot K, harper L et al Ann Int Med 2009)). The study had limited power to detect a difference in relapse. This study describes the long-term outcomes of patients in the CYCLOPS study. METHODS: Long-term outcomes were ascertained retrospectively from 148 patients previously recruited to the CYCLOPS Trial. Data on survival, relapse, immunosuppressive treatment, cancer incidence, bone fractures, thromboembolic disease and cardiovascular morbidity were collected from physician records retrospectively. All patients were analysed according to the group to which they were randomised. RESULTS: Median duration of follow-up was 4.3 years (IQR, 2.95-5.44 years). There was no difference in survival between the two limbs (p=0.92). Fifteen (20.8%) DO and 30 (39.5%) pulse patients had at least one relapse. The risk of relapse was significantly lower in the DO limb than the pulse limb (HR=0.50, 95% CI 0.26 to 0.93; p=0.029). Despite the increased risk of relapse in pulse-treated patients, there was no difference in renal function at study end (p=0.82). There were no differences in adverse events between the treatment limbs. DISCUSSION: Pulse cyclophosphamide is associated with a higher relapse risk than DO cyclophosphamide. However, this is not associated with increased mortality or long-term morbidity. Although the study was retrospective, data was returned in 90% of patients from the original trial.

Published
2016

26. Zeitbezogene Quantitätsanalyse der in PubMed publizierten Artikel über randomisierte kontrollierte Studien inner- und außerhalb der Zahnmedizin

Author

Jung, M, Wissing, M, Motschall, E, and Türp, JC

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Ziele: In der Qualitätshierarchie der externen Evidenz kommt innerhalb der therapeutischen Primärstudien randomisierten kontrollierten Studien (randomized controlled trials, RCTs) die höchste Evidenzstärke zu. Die in den medizinischen Fächern am häufigsten verwendete Meta-Datenbank[zum vollständigen Text gelangen Sie über die oben angegebene URL], Gemeinsam informiert entscheiden; 17. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin

Published
2016
Full Text
View/download PDF

27. Prospective, Randomized Study On Graft Function Comparing Steroid-Free to Calcineurin-Inhibitor-Free Immunosuppressive Treatment After De Novo Kidney Transplantation (PREMIERE)

Author

Peeters, P., Bosmans, J., Weekers, L., Sennesael, J., Dirk RJ Kuypers, Broeders, N., Laecke, S., Wissing, M., Vanhoutte, K., Abramowicz, D., and Internal Medicine Specializations

Subjects
calcineurin-inhibitor-free, steroid-free, de novo kidney transplantation, graft function, PREMIERE, immunosuppressive treatment, prospective randomized study
Abstract

No abstract available

Published
2014

28. Polycystic ovary syndrome and low-grade inflammation with special reference to YKL-40

Author

Aziz, M, Wissing, M L M, Naver, K V, Faber, J, Skouby, S O, Aziz, M, Wissing, M L M, Naver, K V, Faber, J, and Skouby, S O

Abstract

OBJECTIVE: To evaluate the plasma level of YKL-40 in a Danish polycystic ovary syndrome (PCOS) population and to investigate whether YKL-40 is associated with CVD risk factors such as waist circumference, body mass index (BMI), insulin resistance (IR), fasting glucose, fasting insulin, blood lipids and CRP.DESIGN: Cross-sectional study.SETTING: Gynecological clinics at three Danish University Hospitals.PATIENTS: One hundred seventy-one premenopausal women with PCOS recruited consecutively from April 2010 to February 2012. PCOS was diagnosed according to the Rotterdam criteria.MAIN OUTCOME MEASURES: Plasma level of YKL-40 in four phenotypes of PCOS defined by BMI and IR.RESULTS: No statistically significant difference was observed in the plasma level of YKL-40 across the four BMI/IR-phenotypes. Positive associations were observed between YKL-40 and BMI, total and free testosterone, triglycerides, and CRP. Total and free testosterone were independent predictors of YKL-40.CONCLUSION: YKL-40, the marker of low-grade inflammation is not increased in women with PCOS.

Published
2014

29. Identification of new ovulation-related genes in humans by comparing the transcriptome of granulosa cells before and after ovulation triggering in the same controlled ovarian stimulation cycle

Author

Wissing, M L, Kristensen, S G, Andersen, C Y, Mikkelsen, A L, Høst, T, Borup, Rehannah H, Grøndahl, M L, Wissing, M L, Kristensen, S G, Andersen, C Y, Mikkelsen, A L, Høst, T, Borup, Rehannah H, and Grøndahl, M L

Abstract

STUDY QUESTION: Which genes and molecular mechanisms are involved in the human ovulatory cascade and final oocyte maturation?SUMMARY ANSWER: Up-regulated genes in granulosa cells (GC) represented inflammation, angiogenesis, extracellular matrix, growth factors and genes previously associated with ovarian cancer, while down-regulated genes mainly represented cell cycle and proliferation.WHAT IS KNOWN ALREADY: Radical changes occur in the follicle during final follicle maturation after the ovulatory trigger: these range from ensuring an optimal milieu for the oocyte in meiotic arrest to the release of a mature oocyte and remodeling into a corpus luteum. A wide range of mediators of final follicle maturation has been identified in rodents, non-human primates and cows.STUDY DESIGN, SIZE, DURATION: Prospective cohort study including 24 women undergoing ovarian stimulation with the long gonadotrophin-releasing hormone agonist protocol during 2010-2012 at Holbæk Fertility Clinic. Nine paired samples of GC and 24 paired samples of follicular fluid (FF) were obtained before and after recombinant human chorionic gonadotrophin (rhCG) administration.PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine paired (nine arrays before rhCG and nine arrays after rhCG) samples of GC mRNA were amplified and hybridized to Affymetrix Human Gene 1.0 ST GeneChip arrays, compared and bioinformatically analyzed. Eleven selected genes were validated by quantitative reverse transcriptase PCR. FF hormones were analyzed by enzyme-linked immunosorbent assay.MAIN RESULTS AND THE ROLE OF CHANCE: Eleven hundred and eighty-six genes were differentially expressed (>2-fold, P<0.0001, false discovery rate <0.0012) when comparing GC isolated before and 36 h after hCG, among those were genes known to be expressed at ovulation, i.e. ADAMTS1 and HAS2. Many new ovulation-related genes were revealed, such as CD24, ANKRD22, CLDN11 and FBXO32. FF estrogen, androstenedione

Published
2014

30. PULSE VERSUS DAILY ORAL CYCLOPHOSPHAMIDE FOR INDUCTION OF REMISSION IN ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: A RANDOMIZED TRIAL

Author

de Groot, K, Harper, L, Jayne, Dr, Flores Suarez LF, Gregorini, G, Gross, Wl, Luqmani, R, Pusey, Cd, Rasmussen, N, Sinico, Ra, Tesar, V, Vanhille, P, Westman, K, Savage, Co, EUVAS Collaborators Abramowicz, D, Wissing, M, Madhoun, P, Blockmans, D, Stolear, J, Ekstrand, A, Chabova, V, Teasr, V, Rychlik, I, Bataille, P, Puechal, X, Leblau, J, Esnault, Vl, Weidner, S, Rupprecht, H, Schneider, M, Specker, C, Schmitt, W, van der Woude, F, Vischedyck, M, Feighery, C, Garibotto, Giacomo, Santostefano, M, Dadoniene, J, Flores Suarez, L, Hagen, Ec, Oudejans, I, Verburgh, C, Ballarin, J, Mirapeix, E, Valles, M, Bruchfeld, A, Pettersson, E, Eriksson, P, Selga, D, Segelmark, M, Lundberg, I, Svenungsson, E, Chizzolini, C, Adu, D, Savage, C, de Souza, R, and Watts, R.

Published
2009

31. A propos de 2000 greffes rénales a l'U.L.B

Author

Madhoun, P, Wissing, M, Broeders, N, Ghisdal, L, Hoang, A, Loi, P, Michalsky, D, Bollens, R, Donckier, V, Hooghe, L, Janssen, F, Hall, M, Depierreux, M, Kinnaert, P, Vereerstraeten, P, Abramowicz, D, Observerende Klinische wetenschappen, and Faculteit van de Geneeskunde en Farmacie

Subjects
Hospitals, University, Treatment Outcome, Belgium, Cadaver, graft survival, Living Donors, Journal Article, Humans, kidney transplantation, English Abstract, Treatment Failure, Tissue Donors, Retrospective Studies
Abstract

Since 1965, more than 2000 renal transplantations (including more than 100 living-donor transplantations) have been performed at the University of Brussels. An end-stage renal disease patient candidate to renal transplantation will be therefore followed from his enrolment on the waiting list to the long-term post-transplant period. Improvement in the outcome of renal transplantation is achieved due to better knowledge in many fields of medicine, such as immunology, infectious disease, metabolic diseases (hyperlipemia, diabetes mellitus), pharmacology, use of immunosuppressive regimen, a more adequate cardiovascular prevention and treatment. If the best results were achieved with kidneys from living donors, the graft survival rate at the University of Brussels was nearly 80% for the last period (2000-2006). Unfortunately, renal transplantation cannot cure certain comorbid conditions and even may promote them: infectious diseases, neoplasia, metabolic disorders (e.a diabetes mellitus, hyperlipemia). Many efforts have to be done to develop less toxic and more immune selective therapeutic strategies. Living donation and extension of the pool of cadaveric donors will reduce the length of time spent on the waiting list and will significantly impact on mortality and morbidity after kidney transplantation.

Published
2008

32. Time-related quantitative analysis of articles about randomized controlled trials in medicine and dentistry cited in PubMed.

Author

Jung, M., Wissing, M., Motschall, E., and Türp, J. C.

Subjects
RANDOMIZED controlled trials, DENTAL specialties, TEMPOROMANDIBULAR disorders, PERIODONTICS, DENTISTRY, DIAGNOSIS
Abstract

Copyright of Journal of Craniomandibular Function is the property of Quintessence Publishing Company Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2017

33. Guidelines for the treatment and management of new-onset diabetes after transplantation

Author

Wilkinson, A, Davidson, J, Dotta, F, Home, Pd, Keown, P, Kiberd, B, Jardine, A, Levitt, N, Marchetti, Piero, Markell, M, Naicker, S, O'Connell, P, Schnitzler, M, Standl, E, Torregosa, Jv, Uchida, K, Valantine, H, Villamil, F, Vincenti, F, Wissing, M., and Clinical sciences

Subjects
surgical procedures, operative, Cardiovascular diseases, Research Support, Non-U.S. Gov't, diabetes mellitus, organ transplantation, Practice Guidelines as Topic, Journal Article, Humans, Review, Immunosuppressive Agents
Abstract

Although graft and patient survival after solid organ transplantation have improved markedly in recent years, transplant recipients continue to experience an increased prevalence of cardiovascular disease (CVD) compared with the general population. A number of factors are known to impact on the increased risk of CVD in this population, including hypertension, dyslipidemia and diabetes mellitus. Of these factors, new-onset diabetes after transplantation has been identified as one of the most important, being associated with reduced graft function and patient survival, and increased risk of graft loss. In 2003, International Consensus Guidelines on New-onset Diabetes after Transplantation were published, which aimed to establish a precise definition and diagnosis of the condition and recommend management strategies to reduce its occurrence and impact. These updated 2004 guidelines, developed in consultation with the International Diabetes Federation (IDF), extend the recommendations of the previous guidelines and encompass new-onset diabetes after kidney, liver and heart transplantation. It is hoped that adoption of these management approaches pre- and post-transplant will reduce individuals' risk of developing new-onset diabetes after transplantation as well as ameliorating the long-term impact of this serious complication.

Published
2005

36. Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study

Author

Benahmed, A., primary, Kianda, M., additional, Ghisdal, L., additional, Broeders, N., additional, Massart, A., additional, Lemy, A., additional, Mikhalski, D., additional, Hoang, A. D., additional, Donckier, V., additional, Sadis, C., additional, Le Moine, A., additional, Madhoun, P., additional, Racape, J., additional, Wissing, M., additional, and Abramowicz, D., additional

Published
2013
Full Text
View/download PDF

37. Le département médico-chirurgical de Néphrologie Dialyse et Transplantation Rénale

Author

Vanherweghem, J L, Abramowicz, D, Broeders, N, De Pauw, L, Le Moine, A, Nortier, J, Tielemans, C, Wissing, M, Faculteit van de Geneeskunde en Farmacie, Faculteit Economische en Sociale Wetenschappen en Solvay Business School, and Observerende Klinische wetenschappen

Subjects
Hospitals, University, Biomedical Research, Hemodialysis Units, Hospital, Belgium, Journal Article, Humans, kidney transplantation, Kidney Diseases, English Abstract, Review, Surgery Department, Hospital
Abstract

The Department of Nephrology of the Hospital Erasme, opened 25 years ago, is now performing, each year, 22,000 hemodialysis sessions, 800 patient-weeks of peritoneal dialysis treatment and 70 renal grafts. Scientific contributions of the department deal with vascular access for hemodialysis, susceptibility to infections of dialyzed patients, parathyroid surgery, biocompatibility of dialysis membranes, predictive factors of renal graft survival, immunosuppression with monoclonal antibodies, experimental studies of graft tolerance and rejection, toxic nephropathies. The most original contributions are related to anaphylactoïd reactions in hemodialysis by association of acrylonitrile membranes with inhibition of the converting enzyme, to advantages and side effects of OKT3 monoclonal antibody and to discovery and study of the Chinese herbs nephropathy.

Published
2002

38. IFN-gamma, IL-4, IL-10 and IL-12 gene expression in BCG-Leishmania vaccination of Trypanosoma cruzi-infected mice

Author

Araujo, Z, Heremans, H, Stordeur, P, Wissing, M, Goldman, M, Castes, M, Carlier, Y, and Clinical sciences

Subjects
Male, Protozoan Vaccines, Mice, Inbred BALB C, mice, Trypanosoma cruzi, Research Support, Non-U.S. Gov't, interleukin-10, Leishmania mexicana, Gene Expression, Interleukin-12, Interferon-gamma, parasitic diseases, BCG Vaccine, Journal Article, Animals, Chagas Disease, Interleukin-4, RNA, Messenger, Cells, Cultured, Injections, Intraperitoneal, Spleen
Abstract

We have previously shown that vaccination of BALB/c mice with a combination of BCG plus killed Leishmania promastigotes, applied by the i.p. route 10 and 3 days before Trypanosoma cruzi inoculation, prolonged their survival and decreased their parasitaemia. In the present study we show that the BCG-Leishmania vaccine induced higher levels of circulating IFN-gamma in acute and chronic infection of mice [on day 25 and 40 post-infection (p.i.) respectively], in comparison to unvaccinated animals (PBS-treated). Though the IFN-gamma mRNA content of spleen cells of vaccinated and infected mice (on day 25 p.i.) was similar to that of unvaccinated animals, the BCG-Leishmania vaccine enhanced significantly the production of IFN-gamma by spleen cells stimulated with T. cruzi antigens. This effect was observed to a lower extent in BCG- and Leishmania-treated mice. The BCG-Leishmania vaccine reduced the expression of the IL-10 mRNA of splenocytes as soon as day 12 p.i., before the peak parasitaemia. Such this effect was not observed in BCG- or Leishmania-treated animals. On day 25 p.i., the BCG plus Leishmania- or BCG-treatment of mice abolished the capacity of spleen cells to produce IL-10 in response to T. cruzi antigens. The levels of mIL-4 RNA and protein production were not modified in any group of mice. T. cruzi infection in BCG-Leishmania-vaccined mice stimulated an early and high production of IL-12 transcripts in spleen cells during the acute phase of the infection, that was prolonged during the chronic phase of infection. This effect was weaker or absent in BCG- and Leishmania-treated animals, respectively. These results indicate that the BCG-Leishmania vaccine stimulates the production of IL-12 and IFN-gamma, but inhibits that of IL-10 and is without effect on IL-4 when mice are infected with T. cruzi. This highlights the key role of endogenously produced IFN-gamma, IL-10 and IL-12 in the control of T. cruzi acute and chronic infection in mice and the favorable modulation of their balance by a vaccination combining BCG and Leishmania.

Published
2000

39. Quel degré de liberté y a-t-il pour un donneur vivant?

Author

Kinnaert, P, Abramowicz, D, De Pauw, L, Janssen, F, Hall, M, Wissing, M, Hooghe, L, Faculteit Economische en Sociale Wetenschappen en Solvay Business School, and Observerende Klinische wetenschappen

Subjects
Tissue and Organ Procurement, Belgium, informed consent, Religion and Medicine, Cadaver, Living Donors, Journal Article, Humans, kidney transplantation, Ethics, Medical, freedom, English Abstract, decision making
Abstract

The shortage of cadaveric donors has induced a renewed interest in living kidney donation. This paper describes the legal, religious and ethical factors which ensure or restrict the autonomy of the potential donor. We conclude that it is possible with appropriate measures to protect his freedom of choice.

Published
1999

40. Les dioxines: état actuel des connaissances des effets sur la santé

Author

Wissing, M and Observerende Klinische wetenschappen

Subjects
Male, Abnormalities, Drug-Induced, English Abstract, Review, Dioxins, reproduction, Neoplasms, Journal Article, Humans, heterocyclic compounds, Environmental Pollutants, Female, pregnancy, Environmental Health
Abstract

Dioxins are a family of chlorinated aromatic hydrocarbons that are produced during combustion processes in the presence of a chlorine donor and as by-products of the chlorine-processing chemical industries. Several dioxins are extremely stable compounds and persist for years in the environment. Exposure to dioxins occurs mainly via the ingestion of contaminated food. The lipophilic character of dioxins prevents their excretion in the urine and causes their accumulation in body fat. The mechanisms of dioxin action are similar to those of a hormone. Dioxins bind to a specific intracellular receptor and the complex acts as a transcription factor that induces the production of a great number of proteins. Certain dioxins, particularly 2,3,7,8-tetrachlorodibenzo-p-dioxin, are very toxic and able to induce numerous clinical conditions. The carcinogenicity of dioxins is well documented in animal models and has been described in humans after professional and accidental exposures. Recent experimental data also indicatethat dioxins can cause dysfunction of the sexual and thyroid hormone systems and that the administration of dioxins induces several conditions related to hormonal dysfunction. Chronic exposure of female Rhesus monkeys increases the incidence and severity of endometriosis. The administration of dioxins during pregnancy and nursing causes altered development of the reproductive system, decreased spermatogenesis, hypothyroidism and disturbed psychomotor development in the offspring. The particular sensibility of the fetus and newborn is of concern because the exposition to dioxins is particularly important during those periods of life. In humans a series of conditions related to hormonal dysfunction as undescended testis, decreased spermatogenesis, testicular cancer and endometriosis have increased in incidence during the last decades. The chronological parallelism with the appearance of dioxins in the environment suggests that these might exert biological effects at the prevailing level of exposure. Nevertheless this hypothesis is currently unconfirmed by epidemiological studies. The implications of this scientific incertitude for the implementation of preventive measures are briefly discussed.

Published
1998

41. Mycophenolate mofetil

Author

Abramowicz, D, Broeders, N, Wissing, M, Sternon, J, Faculteit van de Geneeskunde en Farmacie, and Observerende Klinische wetenschappen

Subjects
Diarrhea, Graft Rejection, B-Lymphocytes, Clinical Trials as Topic, kidney, T-Lymphocytes, kidney transplantation, Leukopenia, Adrenal Cortex Hormones, Acute Disease, Cyclosporine, incidence, Journal Article, Humans, risk factors, Mycophenolic acid, Cell Division, Immunosuppressive Agents
Abstract

Mycophenolate Mofetil (MMF) is a new immunosuppressive agent that selectively inhibits the proliferation of T and B lymphocytes. The use of MMF in renal transplantation significantly reduced the incidence of acute rejection episodes in the first year after transplantation. The main toxicities of MMF are the occurrence of diarrhea and leucopenia. This potent immunosuppressive agent is devoid of the nephrotoxicity of cyclosporin and of the multiple adverse effects of corticosteroids. Clinical trials are currently in progress to assess whether the use of MMF will allow the discontinuation of cyclosporine or corticosteroid therapy without leading to an increased risk of rejection. If results were positive, MMF would represent a significant advance in the field of renal transplantation.

Published
1998

42. Reproductive (epi)genetics

Author

Lynch, C., primary, Tee, N., additional, Rouse, H., additional, Gordon, A., additional, Sati, L., additional, Zeiss, C., additional, Soygur, B., additional, Bassorgun, I., additional, Goksu, E., additional, Demir, R., additional, McGrath, J., additional, Groendahl, M. L., additional, Thuesen, L., additional, Andersen, A. N., additional, Loft, A., additional, Smitz, J., additional, Adriaenssens, T., additional, Vikesa, J., additional, Borup, R., additional, Mersy, E., additional, Kisters, N., additional, Macville, M. V. E., additional, Engelen, J. J. M., additional, Consortium, S.-E. N. N., additional, Menheere, P. P. C. A., additional, Geraedts, J. P., additional, Coumans, A. B. C., additional, Frints, S. G. M., additional, Aledani, T., additional, Assou, S., additional, Traver, S., additional, Ait-ahmed, O., additional, Dechaud, H., additional, Hamamah, S., additional, Mizutani, E., additional, Suzumori, N., additional, Sugiyama, C., additional, Hattori, Y., additional, Sato, T., additional, Ando, H., additional, Ozaki, Y., additional, Sugiura-Ogasawara, M., additional, Wissing, M., additional, Kristensen, S. G., additional, Andersen, C. Y., additional, Mikkelsen, A. L., additional, Hoest, T., additional, Velthut-Meikas, A., additional, Simm, J., additional, Metsis, M., additional, Salumets, A., additional, Palini, S., additional, Galluzzi, L., additional, De Stefani, S., additional, Primiterra, M., additional, Wells, D., additional, Magnani, M., additional, Bulletti, C., additional, Vogt, P. H., additional, Frank-Herrmann, P., additional, Bender, U., additional, Strowitzki, T., additional, Besikoglu, B., additional, Heidemann, P., additional, Wunsch, L., additional, Bettendorf, M., additional, Jelinkova, L., additional, Vilimova, S., additional, Kosarova, M., additional, Sebek, P., additional, Volemanova, E., additional, Kruzelova, M., additional, Civisova, J., additional, Svobodova, L., additional, Sobotka, V., additional, Mardesic, T., additional, van de Werken, C., additional, Santos, M. A., additional, Eleveld, C., additional, Laven, J. S. E., additional, Baart, E. B., additional, Pylyp, L. Y., additional, Spinenko, L. A., additional, Zukin, V. D., additional, Perez-Sanz, J., additional, Matorras, R., additional, Arluzea, J., additional, Bilbao, J., additional, Gonzalez-Santiago, N., additional, Yeh, N., additional, Koff, A., additional, Barlas, A., additional, Romin, Y., additional, Manova-Todorova, K., additional, Hoz, C. D. l., additional, Mauri, A. L., additional, Nascimento, A. M., additional, Vagnini, L. D., additional, Petersen, C. G., additional, Ricci, J., additional, Massaro, F. C., additional, Cavagna, M., additional, Pontes, A., additional, Oliveira, J. B. A., additional, Baruffi, R. L. R., additional, Franco, J. G., additional, Wu, E. X., additional, Ma, S., additional, Parriego, M., additional, Sole, M., additional, Boada, M., additional, Coroleu, B., additional, Veiga, A., additional, Kakourou, G., additional, Poulou, M., additional, Vrettou, C., additional, Destouni, A., additional, Traeger-Synodinos, J., additional, Kanavakis, E., additional, Yatsenko, A. N., additional, Georgiadis, A. P., additional, McGuire, M. M., additional, Zorrilla, M., additional, Bunce, K. D., additional, Peters, D., additional, Rajkovic, A., additional, Olszewska, M., additional, Kurpisz, M., additional, Gilbertson, A. Z. A., additional, Ottolini, C. S., additional, Summers, M. C., additional, Sage, K., additional, Handyside, A. H., additional, Thornhill, A. R., additional, Griffin, D. K., additional, Chung, M. K., additional, Kim, J. W., additional, Lee, J. H., additional, Jeong, H. J., additional, Kim, M. H., additional, Ryu, M. J., additional, Park, S. J., additional, Kang, H. Y., additional, Lee, H. S., additional, Zimmermann, B., additional, Banjevic, M., additional, Hill, M., additional, Lacroute, P., additional, Dodd, M., additional, Sigurjonsson, S., additional, Lau, P., additional, Prosen, D., additional, Chopra, N., additional, Ryan, A., additional, Hall, M., additional, McAdoo, S., additional, Demko, Z., additional, Levy, B., additional, Rabinowitz, M., additional, Vereczeky, A., additional, Kosa, Z. S., additional, Savay, S., additional, Csenki, M., additional, Nanassy, L., additional, Dudas, B., additional, Domotor, Z. S., additional, Debreceni, D., additional, Rossi, A., additional, Alegretti, J. R., additional, Cuzzi, J., additional, Bonavita, M., additional, Tanada, M., additional, Matunaga, P., additional, Fettback, P., additional, Rosa, M. B., additional, Maia, V., additional, Hassun, P., additional, Motta, E. L. A., additional, Piccolomini, M., additional, Gomes, C., additional, Barros, B., additional, Nicoliello, M., additional, Criscuolo, T., additional, Miyadahira, E., additional, Montjean, D., additional, Benkhalifa, M., additional, Berthaut, I., additional, Griveau, J. F., additional, Morcel, K., additional, Bashamboo, A., additional, McElreavey, K., additional, Ravel, C., additional, Rubio, C., additional, Rodrigo, L., additional, Mateu, E., additional, Mercader, A., additional, Peinado, V., additional, Buendia, P., additional, Milan, M., additional, Delgado, A., additional, Al-Asmar, N., additional, Escrich, L., additional, Campos-Galindo, I., additional, Garcia-Herrero, S., additional, Poo, M. E., additional, Mir, P., additional, Simon, C., additional, Reyes-Engel, A., additional, Cortes-Rodriguez, M., additional, Lendinez, A., additional, Perez-Nevot, B., additional, Palomares, A. R., additional, Galdon, M. R., additional, Ruberti, A., additional, Minasi, M. G., additional, Biricik, A., additional, Colasante, A., additional, Zavaglia, D., additional, Iammarrone, E., additional, Fiorentino, F., additional, Greco, E., additional, Demir, N., additional, Ozturk, S., additional, Sozen, B., additional, Morales, R., additional, Lledo, B., additional, Ortiz, J. A., additional, Ten, J., additional, Llacer, J., additional, Bernabeu, R., additional, Nagayoshi, M., additional, Tanaka, A., additional, Tanaka, I., additional, Kusunoki, H., additional, Watanabe, S., additional, Temel, S. G., additional, Beyazyurek, C., additional, Ekmekci, G. C., additional, Aybar, F., additional, Cinar, C., additional, Kahraman, S., additional, Nordqvist, S., additional, Karehed, K., additional, Akerud, H., additional, Gultomruk, M., additional, Tulay, P., additional, Findikli, N., additional, Yagmur, E., additional, Karlikaya, G., additional, Ulug, U., additional, Bahceci, M., additional, Bargallo, M. F., additional, Arevalo, M. R., additional, Salat, M. M., additional, Barbat, I. V., additional, Lopez, J. T., additional, Algam, M. E., additional, Boluda, A. B., additional, de Oya, G. C., additional, Tolmacheva, E. N., additional, Kashevarova, A. A., additional, Skryabin, N. A., additional, Lebedev, I. N., additional, Semaco, E., additional, Belo, A., additional, Riboldi, M., additional, Luz, L., additional, Nobrega, N., additional, Mazetto, R., additional, Alegretti, J. A., additional, Bibancos, M., additional, Serafini, P., additional, Neupane, J., additional, Vandewoestyne, M., additional, Heindryckx, B., additional, Deroo, T., additional, Lu, Y., additional, Ghimire, S., additional, Lierman, S., additional, Qian, C., additional, Deforce, D., additional, De Sutter, P., additional, Viloria, T., additional, Martinez-Jabaloyas, J. M., additional, Gil-Salom, M., additional, Capalbo, A., additional, Treff, N., additional, Cimadomo, D., additional, Tao, X., additional, Ferry, K., additional, Ubaldi, F. M., additional, Rienzi, L., additional, Scott, R. T., additional, Katzorke, N., additional, Vogt, H. P., additional, Hehr, A., additional, Gassner, C., additional, Paulmann, B., additional, Kowalzyk, Z., additional, Klatt, M., additional, Krauss, S., additional, Seifert, D., additional, Seifert, B., additional, Hehr, U., additional, Lobascio, M., additional, Varricchio, M. T., additional, Rubino, P., additional, Bono, S., additional, Cotarelo, R. P., additional, Spizzichino, L., additional, Colicchia, A., additional, Giannini, P., additional, Suhorutshenko, M., additional, and Rosenstein-Tamm, K., additional

Published
2013
Full Text
View/download PDF

43. Transplantation - clinical

Author

Masson, I., primary, Maillard, N., additional, Alamartine, E., additional, Mariat, C., additional, Delanaye, P., additional, Catalano, C., additional, Lemy, A., additional, Lionet, A., additional, Hiesse, C., additional, De Meyer, M., additional, Kianda, M., additional, Toungounz, M., additional, Wissing, M., additional, Racape, J., additional, Abramowicz, D., additional, Jeong, J. H., additional, Yoon, C. S., additional, Kong, J. M., additional, Choi, W. Y., additional, Whang, E. J., additional, Lee, D. R., additional, Ahn, J., additional, Obi, Y., additional, Hamano, T., additional, Ichimaru, N., additional, Tomida, K., additional, Fujii, N., additional, Matsui, I., additional, Kaimori, J.-y., additional, Rakugi, H., additional, Takahara, S., additional, Isaka, Y., additional, Tsubakihara, Y., additional, De Vusser, K., additional, Pieters, N., additional, Janssen, B., additional, Lerut, E., additional, Nawroth, T., additional, Kuypers, D., additional, Vanrenterghem, Y., additional, and Naesens, M., additional

Published
2013
Full Text
View/download PDF

47. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/CHIR - Département de chirurgie, Abramowicz, D., Mourad, Michel, Vanrenterghem, Y., Squifflet, Jean-Paul, Kuypers, Delphine, Meurisse, M, Wissing, M., UCL - Cliniques universitaires Saint-Luc, UCL - MD/CHIR - Département de chirurgie, Abramowicz, D., Mourad, Michel, Vanrenterghem, Y., Squifflet, Jean-Paul, Kuypers, Delphine, Meurisse, M, and Wissing, M.

Abstract

This single-arm, open-label, pilot study was designed to assess the efficacy and cardiovascular safety profile of daclizumab, a humanized monoclonal interleukin (IL)-2R alpha antibody, in combination with mycophenolate mofetil (MMF), tacrolimus, and early corticosteroid withdrawal in renal transplant recipients. Seventy-nine renal allograft recipients were treated with daclizumab (1 mg/kg; five doses starting on the day before transplant and then every two weeks), MMF (1 g b.i.d.), tacrolimus (0.2 mg/kg/d), and low-dose prednisolone, which was withdrawn at day 150 after transplant. The rate of acute rejection was determined at 12 months. Lipid profile, oral glucose tolerance, and adverse events were monitored. Of the 76 patients eligible for analysis, eight (10.5%) developed biopsy-proven acute rejection (BPAR). Ten (13.2%) experienced clinical and/or BPAR. Corticosteroids were withdrawn completely in 91% of patients at 12 months. Graft and patient survival were 97.5% and 98.7% respectively. Mean total cholesterol and triglycerides were significantly lower at 12 months post-transplant than at baseline (201 +/- 47.5 vs. 190.8 +/- 43.6 mg/dL, p = 0.005 and 196.2 +/- 133.2 vs. 144.5 +/- 76.8 mg/dL, p < 0.001, respectively). Mean hemoglobin A(1c) levels did not differ between baseline (5.54%) and 12 months (5.48%). New-onset post-transplant diabetes mellitus occurred in 6.6% of the non-diabetic transplanted patients. The proportion of patients with abnormal oral glucose tolerance test (OGTT) was 47% at 3 months and 39% at 12 months (p = NS). Daclizumab induction in combination with MMF, tacrolimus, and low-dose (followed by withdrawal) prednisolone appears to be effective and safe in patients receiving renal allografts. The regimen appears to be associated with a favorable cardiovascular profile.

Published
2005

49. Early neutralization of IL-4 but not of IL-10 abrogates neonatal induction of transplantation tolerance in mice

Author

Donckier, V, Wissing, M, Abramowicz, D, Bruyns, C, Vanderhaeghen, M L, Lybin, M, Goldman, M, and Clinical sciences

Subjects
Mice, Inbred BALB C, immunosuppression, mice, Mice, Inbred A, Research Support, Non-U.S. Gov't, Antibodies, Monoclonal, Enzyme-Linked Immunosorbent Assay, Immunoglobulin E, Animals, Newborn, Lymphocyte Transfusion, Journal Article, Animals, Skin transplantation, Interleukin-4, Crosses, Genetic
Published
1995

50. Emergence of Th2-like cells after anti-CD3 monoclonal antibody administration in mice

Author

Wissing, M, Alegre, M L, Abramowicz, D, Willems, F, Donckier, V, Vanderhaeghen, M L, Leo, O, Goldman, M, Clinical sciences, and Faculty of Physical Education and Physical Therapy

Subjects
Mice, Inbred BALB C, immunosuppression, mice, Time Factors, CD3 Complex, T-Lymphocytes, Research Support, Non-U.S. Gov't, interleukin-10, Antibodies, Monoclonal, Drug Administration Schedule, Interferon-gamma, Journal Article, Animals, Cytokines, Interleukin-2, Comparative Study, Interleukin-4
Published
1995

Catalog

Books, media, physical & digital resources
See catalog results